#USA #New York #Heart Disease #Cardiol Therapeutics #CardiolRx

Cardiol Therapeutics to Join H.C. Wainwright Conference

Cardiol Therapeutics Inc., a late-stage life sciences company listed on NASDAQ (CRDL) and TSX, is excited to announce its participation in a Fireside Chat at the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference, scheduled for May 19, 2026, at 1:30 PM EDT, in New York City. This event is an excellent opportunity for investors and stakeholders to get insights into the company's groundbreaking work in anti-inflammatory and anti-fibrotic therapies aimed at treating heart disease.

Understanding Cardiol Therapeutics’ Focus

The primary focus of Cardiol Therapeutics is the development of therapies that address critical issues surrounding heart disease, leveraging their lead product, CardiolRx™. This small-molecule drug candidate targets the inflammasome pathway, which has significant implications for the inflammation and fibrosis processes associated with conditions like pericarditis, myocarditis, and heart failure.

The Importance of the MAVERIC Program

One critical initiative underway is the MAVERIC Program, which evaluates the efficacy of CardiolRx™ in treating recurrent pericarditis. This inflammatory condition leads to debilitating symptoms like chest pain and fatigue, severely affecting patients' quality of life and often resulting in emergency interventions. The program includes the completed Phase II MAvERIC-Pilot study and currently ongoing pivotal Phase III MAVERIC trial. Remarkably, the U.S. FDA has recognized CardiolRx™ by granting it Orphan Drug Designation for recurrent pericarditis treatment, highlighting the therapy’s promise in addressing an unmet medical need.

Insights from the ARCHER Program

Additionally, the company is conducting studies under the ARCHER Program, which focuses on the application of CardiolRx™ for acute myocarditis—a leading cause of sudden cardiac death, especially among younger adults. The completed Phase II ARCHER study has provided valuable data regarding the safety and effectiveness of the drug in tackling this serious health threat.

Advancement of CRD-38

Apart from CardiolRx™, Cardiol Therapeutics is developing another innovative formulation, CRD-38. This subcutaneous drug is designed to treat inflammatory heart diseases, including heart failure, which remains a leading public health concern with astronomical healthcare costs in the U.S., exceeding $30 billion annually.

Engaging with Investors

The upcoming Fireside Chat is a pivotal event for Cardiol Therapeutics as they engage with current and potential investors. Attendees will learn about the company's strategic roadmap, ongoing clinical trials, and future directions. A live stream of the session will be available on the Cardiol Therapeutics website, ensuring accessibility for a wider audience. Furthermore, a recording of the session will be available for 90 days post-event, allowing for continued engagement beyond the conference.

Conclusion

In an era where heart diseases are escalating globally, the work being done by Cardiol Therapeutics offers hope for improved treatment options. The participation in this significant investor conference reflects the company’s commitment to transparency and innovation in the pharmaceutical industry. Investors and interested parties are encouraged to learn more about Cardiol Therapeutics and its ongoing research initiatives by visiting their official website at cardiolrx.com.

As Cardiol Therapeutics prepares for the conference, all eyes will be on their advancement in the fight against heart disease, a sector that continues to require urgent and effective solutions.